Drugs / Gemcabene
Gemcabene
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02587416 | Nov → Dec 2002 | hyperlipoproteinemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02587390 | May → Jul 2000 | hyperlipidemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02587364 | Apr → Sep 1999 | hyperlipidemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03508687 | Mar 2018 → Jul 2019 | familial partial lipodystrophy, hypertriglyceridemia, metabolic dysfunction-associated steatohepatitis | Elif Oral | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT03436420 | Mar 2018 → Aug 2019 | NAFLD1 | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT02944383 | Dec 2016 → Jan 2018 | hyperlipidemia, combined, 2, hypertriglyceridemia 2 | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02634151 | Nov 2016 → Jun 2017 | hyperlipidemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02722408 | Jun 2016 → Apr 2017 | homozygous familial hypercholesterolemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02591836 | Jan → Jun 2003 | hyperlipidemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02586168 | Jul → Oct 2001 | — | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02571257 | Aug 2000 → Apr 2002 | hyperlipidemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02585869 | Dec 1999 → Jun 2001 | hyperlipidemia, hypertriglyceridemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gemcabene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03436420 ↗ |
| Known as | CI-1027 | “The Effect of Gemcabene (CI-1027) on Insulin Sensitivity in Nondiabetic Subjects” NCT02586168 ↗2“Gemcabene (also known as CI-1027) treatment on stable background statin therapy” NCT02571257 ↗ “300 mg and 900 mg Gemcabene (CI-1027) Administration” NCT02587416 ↗ |
| Known as | GEMCABENE CALCIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110686 ↗ |
| Known as | Gemcabeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110686 ↗ |
| Known as | PD-0072953 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110686 ↗ |
| Known as | PD-072953-0038 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110686 ↗ |
| Modality | Small molecule | — CHEMBL2110686 ↗ |
| Route | Oral | “3x300 mg Gemcabene tablets orally once daily (QD) for 15 days” NCT02587390 ↗ |